日本套细胞淋巴瘤和慢性淋巴细胞白血病患者对治疗的看法。

IF 0.9 Q4 HEMATOLOGY Journal of Clinical and Experimental Hematopathology Pub Date : 2024-06-27 Epub Date: 2024-05-15 DOI:10.3960/jslrt.24016
Toru Kiguchi, Yasushi Hiramatsu, Shuichi Ota, Michihiro Uchiyama, Moe Matsuo, Miyu Okamura, Shimpei Morimoto, Yoshinori Tanizawa, Masaomi Tajimi, Nalin Payakachat
{"title":"日本套细胞淋巴瘤和慢性淋巴细胞白血病患者对治疗的看法。","authors":"Toru Kiguchi, Yasushi Hiramatsu, Shuichi Ota, Michihiro Uchiyama, Moe Matsuo, Miyu Okamura, Shimpei Morimoto, Yoshinori Tanizawa, Masaomi Tajimi, Nalin Payakachat","doi":"10.3960/jslrt.24016","DOIUrl":null,"url":null,"abstract":"<p><p>The increasing number of treatment options for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Japan underscores the critical need to comprehend their treatment preferences. In this study, individual semi-structured interviews with 20 Japanese patients with diagnosis of MCL or CLL/SLL were conducted and qualitatively analyzed to elicit concepts important for patients regarding treatment selection. Although effectiveness and safety were imperative for treatment selection, convenience and quality of life were also reported as important attributes. Over the course of their disease journey, patients reported diverse and changing preferences in terms of treatment characteristics. Additionally, there was a discrepancy between their desired and actual levels of involvement in shared decision-making with physicians about treatment choices. Optimal personalized care for better outcomes of patients with MCL and CLL/SLL hinges on healthcare professionals acknowledging individual patient needs and preferences within their cultural, societal and personal context.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303965/pdf/","citationCount":"0","resultStr":"{\"title\":\"Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan.\",\"authors\":\"Toru Kiguchi, Yasushi Hiramatsu, Shuichi Ota, Michihiro Uchiyama, Moe Matsuo, Miyu Okamura, Shimpei Morimoto, Yoshinori Tanizawa, Masaomi Tajimi, Nalin Payakachat\",\"doi\":\"10.3960/jslrt.24016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The increasing number of treatment options for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Japan underscores the critical need to comprehend their treatment preferences. In this study, individual semi-structured interviews with 20 Japanese patients with diagnosis of MCL or CLL/SLL were conducted and qualitatively analyzed to elicit concepts important for patients regarding treatment selection. Although effectiveness and safety were imperative for treatment selection, convenience and quality of life were also reported as important attributes. Over the course of their disease journey, patients reported diverse and changing preferences in terms of treatment characteristics. Additionally, there was a discrepancy between their desired and actual levels of involvement in shared decision-making with physicians about treatment choices. Optimal personalized care for better outcomes of patients with MCL and CLL/SLL hinges on healthcare professionals acknowledging individual patient needs and preferences within their cultural, societal and personal context.</p>\",\"PeriodicalId\":45936,\"journal\":{\"name\":\"Journal of Clinical and Experimental Hematopathology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303965/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical and Experimental Hematopathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3960/jslrt.24016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Experimental Hematopathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3960/jslrt.24016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在日本,套细胞淋巴瘤(MCL)和慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)患者的治疗选择越来越多,这凸显了了解他们治疗偏好的迫切需要。本研究对 20 名确诊为 MCL 或 CLL/SLL 的日本患者进行了个人半结构式访谈,并对访谈内容进行了定性分析,以了解患者在治疗选择方面的重要概念。虽然有效性和安全性是选择治疗的必要条件,但方便性和生活质量也是重要因素。在疾病的治疗过程中,患者对治疗特点的偏好多种多样且不断变化。此外,在与医生共同决策治疗选择方面,患者的期望参与度与实际参与度之间也存在差异。要为 MCL 和 CLL/SLL 患者提供更好的治疗效果,最佳的个性化护理取决于医疗保健专业人员是否承认患者在其文化、社会和个人背景下的个人需求和偏好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan.

The increasing number of treatment options for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Japan underscores the critical need to comprehend their treatment preferences. In this study, individual semi-structured interviews with 20 Japanese patients with diagnosis of MCL or CLL/SLL were conducted and qualitatively analyzed to elicit concepts important for patients regarding treatment selection. Although effectiveness and safety were imperative for treatment selection, convenience and quality of life were also reported as important attributes. Over the course of their disease journey, patients reported diverse and changing preferences in terms of treatment characteristics. Additionally, there was a discrepancy between their desired and actual levels of involvement in shared decision-making with physicians about treatment choices. Optimal personalized care for better outcomes of patients with MCL and CLL/SLL hinges on healthcare professionals acknowledging individual patient needs and preferences within their cultural, societal and personal context.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.00
自引率
6.70%
发文量
25
审稿时长
11 weeks
期刊最新文献
Clinicopathological and genetic analyses of thyroid large B-cell lymphoma in a Japanese population. Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease. Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan. Autopsy case of cardiac mantle cell lymphoma presenting with recurrent pulmonary tumor embolism after chemotherapy. Comparison of pathophysiological differences in TAFRO syndrome with or without lymphadenopathy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1